WCN26-1861 ATRASENTAN VS PLACEBO IN SUBGROUPS OF PATIENTS FROM EAST ASIA WITH IgA NEPHROPATHY (IgAN): INTERIM DATA FROM THE PHASE III ALIGN TRIAL

the monoclonal IgM, potentially present at levels below the detection threshold, may predispose it to glomerular deposition.This case demonstrates that kidney disease can progress to nephrotic syndrome due to IgM-PGNMID despite the stable disease activity of the underlying LPL.Furthermore, IgM-PGNMID is associated with a poor kidney prognosis, with a median kidney survival of 44 months.More preserved kidney function at the time of PGNMID diagnosis has been associated with better kidney outcomes, suggesting that early diagnosis is crucial.Even during hematologic remission, kidney disease can persist or progress.This highlights the critical need for close collaboration between hematologists and nephrologists to ensure early diagnosis by kidney biopsy and to determine the optimal treatment strategy.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.